Brazil's Health Agency Bans Counterfeit Mounjaro Pens, Recalls Paramol Batch
/https://i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2026/t/B/KMVgqNQOypWhK0v6BSdw/edicao-imagens-g1-23-.png)
Brazil's National Health Surveillance Agency (Anvisa) has issued a series of regulatory actions, including recalls and suspensions, for various medications and medical devices due to identified irregularities. Notably, the agency has prohibited the sale, distribution, and use of counterfeit Mounjaro pens, specifically those with lot number D881474 and serial number 302199651396, as this combination is incompatible with the original product. This action was prompted by a report from Eli Lilly do Brasil, the drug's registered holder. Anvisa also ordered the recall and suspension of lot 114053 of Paramol 750 mg, citing quality deviations including the presence of mold-contaminated tablets. Furthermore, Anvisa has mandated the recall and suspension of all lots for several medical devices, including Cryo.On, Corneal Chamber, GIS Kit, Gás GOT C3F8, Gás GOT SF6, HPF Perfluorocarbono, RS-OIL, Twin, and View ILM. These measures stem from a sanitary inspection of Italian manufacturer AL.CHI.MI.A. S.R.L., which found products manufactured in violation of health regulations. Finally, Anvisa has placed a precautionary embargo on lot 5304259 of the BD Angiocath medical device following an unsatisfactory fiscal analysis of its surface verification.
Anvisa's decisive actions highlight the critical role of regulatory bodies in safeguarding public health against substandard and counterfeit medical products. The agency's proactive stance in identifying and acting upon discrepancies in drug and device manufacturing, whether due to counterfeiting or quality control failures, demonstrates a commitment to consumer safety. The systematic recall of multiple medical devices manufactured by AL.CHI.MI.A. S.R.L. suggests potential systemic issues within that company's production processes or adherence to international regulatory standards. These interventions, while necessary, underscore the ongoing challenges in global supply chain integrity and the persistent threat of illicit pharmaceutical markets. Moving forward, enhanced international cooperation and advanced verification technologies will be crucial to preemptively detect and mitigate such risks, ensuring that patients consistently receive safe and effective treatments.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.